AFT Pharmaceuticals : Crystawash Extend distribution in UAE, Kuwait, Oman and KenOpens in a new Window

12 April 2021

Crystawash® Extend distribution in UAE, Kuwait, Oman and Kenya.

AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces it has signed agreements to distribute its long-acting hand sanitiser Crystawash® Extend in the United Arab Emirates, Kuwait, Oman and Kenya.

In a move that reflects the growing importance of Asian markets to AFT, the company also announces it has appointed a Business Manager for Promoted Products in Asia based out of Hong Kong.

Crystawash Extend

The Crystawash Extend agreements are with Germany's Pharma Bavaria International GmbH, which has well established distribution networks in various countries in the Middle East and Africa.

AFT developed Crystawash Extend, a long-lasting hand sanitiser, to overcome the shortcomings of traditional alcohol-based sanitisers, which need to be applied repeatedly to provide long-lasting protection.

The product, which has been found by independent laboratories to kill 99.99% of germs on immediate contact and display 24-hour residual efficacy against germs evidenced by testing on synthetic skin1,2,3, was launched in Australia and New Zealand earlier this year.

AFT Pharmaceuticals Managing Director Dr Hartley Atkinson said: "We are pleased with the new deal for Crystawash Extend with Pharma Bavaria. It demonstrates how we can leverage our international networks of partnerships to build distribution of our unique products.

"With the outbreak of the Covid-19 pandemic, the world has seen a surge in demand for hand sanitiser. While there may be some moderation of demand as the pandemic is brought under control, we believe the pandemic is also entrenching new standards of public health and personal hygiene practices that include the regular use of hand sanitisers.

"Crystawash Extend meets this demand and does so in a way that is superior to existing technologies. It is great example of AFT working to deliver on its mission to improve global health outcomes."

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand

Incorporated in New Zealand ARBN: ARBN 609 017 969 [e-mail]

AFT is targeting sales of Crystawash Extend in countries covered by this new distribution agreement to commence in the current financial year.

Building AFT's Presence in Asia

AFT has appointed Lorraine Corr-Poppleton as the company's Asia Business Manager, Promoted Products, based in Hong Kong to spearhead the company's presence in the region. This will help serve our customers and partners in the seven territories in Asia where we have licensing and distribution agreements in addition to our own operations in Singapore, Malaysia and Hong Kong.

It will also help AFT to strengthen is relationships and partnerships in mainland China where we are seeking regulatory approval for a number of products and where we launched our online TMall (www.tmall.com) presence last year.

"Lorraine has spent the last six years working throughout the region developing and growing consumer products, it is great to have her join the AFT team and to benefit from the relationships she enjoys in the region," Dr Atkinson said.

For and on behalf of AFT Pharmaceuticals limited by Malcolm Tubby, Chief Financial Officer.

For more information:
Investors	Media
Dr Hartley Atkinson	Richard Inder
Managing Director	The Project
AFT Pharmaceuticals	Tel: [phone]
Tel: [phone]

About AFT Pharmaceuticals

AFT is a growing multinational pharmaceutical business with a broad range of products, both developed itself and in-licensed from third parties. AFT's products cover all major pharmaceutical distribution channels: over-the-counter, prescription and hospital. Historically, AFT's home markets have been Australia, New Zealand and South-East Asia. However, the company is out-licensing its own products to licensees and distributors to sell in an increasing number of countries around the world. The company's intensive Research and Development programme forms the basis of its

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand

Incorporated in New Zealand ARBN: ARBN 609 017 969 [e-mail]

international sales strategy. For more information about the company, visit our website www.aftpharm.com.

About Pharma Bavaria International GmbH

Pharma Bavaria International GmbH operates in more than 45 countries. With a strong focus on growth regions such as the Middle East, Africa, South-East Asia, CIS countries and other emerging economies Pharma Bavaria's portfolio of prescription medicines includes anti-infectives,analgesic/anti-inflammatory, flu and cold, gastroenterology, oncology, cardiology and women's healthcare areas.

References

1. VITRO-SKIN®;Florida Suncare Testing, Inc. IMS Division. https://ims-usa.com/vitro-skin-substrates/vitro-skin/
2. AFT Pharmaceuticals/AsureQuality Laboratory Services, New Zealand microbiological effectiveness study evaluating residual killing activity against transient microbial skin flora on synthetic skin.
3. Time Kill Test conducted by Eurofins BioPharma Product Testing, Australia; Protocol: TMD-110, EN 13727

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand

Incorporated in New Zealand ARBN: ARBN 609 017 969 [e-mail]